Ningbo, China – Recently, a delegation from the Health Industry Chapter of the Ningbo Professional Managers Association visited Zhejiang Tianyuan Biotechnology Co., Ltd. for an inspection and exchange. General Manager Jiao Mingming and his team warmly received the guests, with both parties engaging in discussions to explore new opportunities for collaboration.

      Accompanied by General Manager Jiao Mingming and other senior executives, the delegation—including Vice Presidents Yan Shaogen, Mao Xuefeng, and He Shengnian, Standing Director Leng Deqian, as well as guests Min Wu and Tianpei Zhao from Cihua Zhenpin, and Ruipeng Lai, General Manager of Wukong Healthcare—toured Tianyuan Bio's cell technology exhibition hall and laboratories. They gained a detailed understanding of the company's technological advantages, product portfolio, and scientific research achievements, expressing high recognition of Tianyuan Bio's leading position in the biomedical field.

      During the subsequent symposium, representatives from both sides introduced their respective team members. General Manager Jiao Mingming highlighted the "Ningbo University Biopharmaceutical Innovation Research Institute," jointly established by Tianyuan Bio and Ningbo University, and emphasized the company's industry-leading role in setting the association standard for immunity assessment. He also presented the latest advancements in Tianyuan Bio's umbilical cord stem cell storage, immune cell storage, iPS artificially induced pluripotent stem cells, self-developed cell-derived products, and functional foods.

      Vice President Yan spoke highly of Tianyuan Bio's integrated "industry-academia-research-medicine" model and its scientific research strength. He stated that the Health Industry Chapter would integrate channel resources to help promote high-quality cell technology to the general public. Representatives from the chapter showed strong interest in Tianyuan Bio's product series, noting that these innovative offerings align well with the business needs of their member enterprises.

      The two sides held in-depth discussions on business directions and models, ultimately reaching preliminary cooperation intentions. This collaboration will leverage the respective strengths of both parties, achieve resource sharing and mutual benefits, and jointly drive innovation in the health industry, enabling cell technology to benefit more families.

Zhejiang Tianyuan Biotechnology Co., Ltd., founded in 2017, is a national high-tech enterprise dedicated to cell research, development, production, operation, and service. It possesses valuable resource banks including an HLA Umbilical Cord Matching Library, iPS Seed Cell Bank, and Cancer Cell Bank. The company is the drafting unit for the National Health Commission's association standard on immune function assessment methods. In collaboration with the National Health Commission's Research Institute, it has co-established a Joint Laboratory for Metabolic Immunity Monitoring. Furthermore, it serves as important research and service platforms, including the Ningbo Storage Center of the National Stem Cell Transformation Resource Bank and the Achievement Transformation Center of the National Health Commission's Research Institute.